{"id":330303,"date":"2021-01-10T01:00:00","date_gmt":"2021-01-10T00:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/erenumab-shows-good-results-compared-to-topiramate\/"},"modified":"2021-01-10T01:00:00","modified_gmt":"2021-01-10T00:00:00","slug":"erenumab-shows-good-results-compared-to-topiramate","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/erenumab-shows-good-results-compared-to-topiramate\/","title":{"rendered":"Erenumab shows good results compared to topiramate"},"content":{"rendered":"

Migraine prophylaxis with CGRP antibodies is characterized above all by a rapid onset of action and good tolerability. A phase IV comparative study evaluated erenumab against the anticonvulsant topiramate in patients with episodic and chronic migraine. The results confirm the value of the antibody against the CGRP receptor as a safe and effective treatment.<\/strong><\/p>\n

<\/p>\n

The CGRP receptor antibody erenumab (Aimovig\u00ae) is used for the prophylaxis of episodic and chronic migraine. Whether this protects better against migraine attacks than agents previously prescribed for prophylaxis was analyzed in a post-approval study. The study included 777 subjects who received either erenumab subcutaneously at a dose of 70 mg or 140 mg (given every four weeks) or topiramate orally at 50 to 100 mg\/day. Patients who were treatment-na\u00efve and patients who had already failed up to three prophylactic migraine therapies suffering from \u22654 monthly migraine days (MMDs) were included. The primary study endpoint was treatment discontinuation due to adverse events. The secondary endpoint was defined as the proportion of patients with a 50% reduction in monthly migraine days. During the 24-week treatment period, the CGRP receptor antibody was found to be better tolerated and more effective than topiramate and resulted in fewer treatment discontinuations. This was also reflected in the reduction of MMDs. Here, a greater proportion of patients achieved at least a 50% reduction in their MMDs.<\/p>\n

Calcitonin gene-related peptide (CGRP) is a messenger substance that is released in increased amounts during a migraine attack and plays a central role as an inflammatory protein in migraine. The proinflammatory neuropeptide is responsible for vasodilatation. The monoclonal antibody now specifically targets the CGRP receptor and can thus inhibit the process.<\/p>\n

Source: “HER-MES CLINICAL TRIAL. HER-MES is the first randomized, double blind, head-to-head study of Aimovig\u00ae (erenumab) against topiramate in patients with episodic and chronic migraine”.<\/em><\/p>\n

– Novartis<\/em><\/p>\n

 <\/p>\n

Further reading:<\/p>\n